These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33907631)

  • 1. Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model.
    Domingos-Pereira S; Roh V; Hiou-Feige A; Galliverti G; Simon C; Tolstonog GV; Nardelli-Haefliger D
    Oncoimmunology; 2021 Apr; 10(1):1912473. PubMed ID: 33907631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors.
    Domingos-Pereira S; Galliverti G; Hanahan D; Nardelli-Haefliger D
    J Immunother Cancer; 2019 May; 7(1):122. PubMed ID: 31060612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice.
    Galliverti G; Tichet M; Domingos-Pereira S; Hauert S; Nardelli-Haefliger D; Swartz MA; Hanahan D; Wullschleger S
    Cancer Immunol Res; 2018 Nov; 6(11):1301-1313. PubMed ID: 30131378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
    Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
    Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.
    Peng S; Xing D; Ferrall L; Tsai YC; Roden RBS; Hung CF; Wu TC
    mBio; 2022 Feb; 13(1):e0325221. PubMed ID: 35089069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
    Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
    Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
    Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
    Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice.
    Decrausaz L; Revaz V; Bobst M; Corthésy B; Romero P; Nardelli-Haefliger D
    Int J Cancer; 2010 May; 126(10):2469-78. PubMed ID: 19816937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.
    Bartkowiak T; Singh S; Yang G; Galvan G; Haria D; Ai M; Allison JP; Sastry KJ; Curran MA
    Proc Natl Acad Sci U S A; 2015 Sep; 112(38):E5290-9. PubMed ID: 26351680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16
    Salomon N; Selmi A; Grunwitz C; Kong A; Stanganello E; Neumaier J; Petschenka J; Diken M; Kreiter S; Türeci Ö; Sahin U; Vascotto F
    Cancer Immunol Immunother; 2022 Aug; 71(8):1975-1988. PubMed ID: 34971406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
    Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC).
    Chandra J; Woo WP; Finlayson N; Liu HY; McGrath M; Ladwa R; Brauer M; Xu Y; Hanson S; Panizza B; Frazer IH; Porceddu SV
    Cancer Immunol Immunother; 2021 Mar; 70(3):743-753. PubMed ID: 32918586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV
    Dorta-Estremera S; Chin RL; Sierra G; Nicholas C; Yanamandra AV; Nookala SMK; Yang G; Singh S; Curran MA; Sastry KJ
    Cancer Res; 2018 Sep; 78(18):5327-5339. PubMed ID: 30054333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.
    Esquerré M; Bouillette-Marussig M; Goubier A; Momot M; Gonindard C; Keller H; Navarro A; Bissery MC
    PLoS One; 2017; 12(3):e0174038. PubMed ID: 28301611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
    Wick DA; Webb JR
    Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.
    Zeng Q; Peng S; Monie A; Yang M; Pang X; Hung CF; Wu TC
    Hum Gene Ther; 2011 Jul; 22(7):809-19. PubMed ID: 21128743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model.
    Ishida E; Lee J; Campbell JS; Chakravarty PD; Katori Y; Ogawa T; Johnson L; Mukhopadhyay A; Faquin WC; Lin DT; Wirth LJ; Pierce RH; Pai SI
    Cancer Immunol Immunother; 2019 Aug; 68(8):1273-1286. PubMed ID: 31243491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.
    Jindra C; Huber B; Shafti-Keramat S; Wolschek M; Ferko B; Muster T; Brandt S; Kirnbauer R
    PLoS One; 2015; 10(9):e0138722. PubMed ID: 26381401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.